Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pelacarsen in Calcific Aortic Valve Stenosis
NCT05646381Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Mar 2024
- Primary completion
- Mar 2030
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 15
01
Overview
A Phase 2 trial of pelacarsen in calcific aortic valve stenosis (CAVS), sponsored by Novartis. Started Mar 2024; status: recruiting.
02
Drugs
pelacarsen
03
Conditions
calcific aortic valve stenosis (CAVS)
Beyond the preview
Go deeper on NCT05646381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646381.